Asia-Pacific DNA Vaccine Market to Reach $213.4 Million by 2035

Published: Mar 2026

Asia-Pacific DNA vaccine market was valued at $144.6 million in 2025 and is projected to reach $213.4 million by 2035, expanding at a CAGR of 4.1% during the forecast period from 2026 to 2035. The Asia-Pacific DNA vaccine market is expanding in response to the sustained burden of infectious diseases and the need for rapid, adaptable vaccine technologies. DNA vaccines, particularly plasmid-based platforms, are gaining policy and research attention due to their design flexibility, thermal stability profile, and scalable manufacturing potential. Regional governments are strengthening domestic vaccine capabilities as part of pandemic preparedness and biosecurity frameworks. This strategic shift directly supports growth across both human DNA vaccine and plasmid DNA technology segments within the market. As infectious disease control remains a public health priority, DNA vaccine innovation is becoming structurally embedded in regional immunization strategies.

Browse the full report description of “Asia-Pacific DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, and Human DNA Vaccine), by Technology (Plasmid DNA Vaccines Technology, and Plasmid DNA Delivery Technology), by Application (Oncology, Infectious Diseases, and Others), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/asia-pacific-dna-vaccines-market

According to the World Health Organization’s Global Tuberculosis Report 2025, an estimated 10.7 million people fell ill with tuberculosis in 2024, with the South-East Asia region accounting for 34% and the Western Pacific region contributing 27% of all TB cases globally. This reflects persistent infectious disease incidence across the Asia-Pacific that underscores ongoing vaccine development needs. In addition, over 1.23 million people died from TB in 2024, maintaining it as a major health threat requiring advanced immunization solutions. Government agencies across countries such as China and India have reinforced investment in next-generation vaccine research under national biotechnology missions and public health preparedness plans during 2024–2025. These official statistics and policy actions collectively reinforce the strategic relevance of DNA vaccine platforms in the region.

Market Coverage

  • The market number available for – 2025-2035
  • Base year- 2025
  • Forecast period- 2026-2035
  • Segment Covered-
    • Type
    • Technology
    • Application
  • Competitive Landscape – CanSino Biologics Inc., GeneOne Life Science Inc., Inovio Pharmaceuticals, Inc., Samsung Biologics, Zydus Lifesciences Ltd., among others

Key questions addressed by the report.

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Asia-Pacific DNA Vaccine Market Report Segment

By Type

  • Animal DNA Vaccine
  • Human DNA Vaccine

By Technology

  • Plasmid DNA Vaccines Technology
  • Plasmid DNA Delivery Technology

By Application

  • Oncology
  • Infectious Diseases
  • Others

Asia-Pacific DNA Vaccine Market Report Segment by Country

  • China
  • India
  • Japan
  • South Korea
  • Australia and New Zealand
  • ASEAN Economies
  • Rest of Asia-Pacific

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-dna-vaccines-market